Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing can feel like decoding lab notes—especially when Aptose Biosciences packs pages with trial protocols, burn-rate tables, and partnership milestones. If you have ever searched for “Aptose Biosciences SEC filings explained simply” or wondered how an 8-K on new AML data might move the stock, you are not alone.
Stock Titan solves that problem. Our platform delivers real-time alerts the moment an Aptose Biosciences 8-K material events explained notice hits EDGAR, surfaces cash-runway insights from every Aptose Biosciences quarterly earnings report 10-Q filing, and condenses the 300-page Aptose Biosciences annual report 10-K simplified into an easy-to-scan summary. Need insider sentiment? We stream Aptose Biosciences Form 4 insider transactions real-time so you can track each Aptose Biosciences executive stock transactions Form 4 before the market reacts. Our AI-powered summaries translate technical oncology jargon into plain English, letting you focus on decisions, not document mining.
Whether you are comparing quarter-over-quarter R&D spend, checking a Aptose Biosciences proxy statement executive compensation, or reviewing Aptose Biosciences insider trading Form 4 transactions, every filing is accompanied by concise bullet points, red-flag alerts, and trend charts. Investors use these tools to time capital raises, monitor dilution risk, and gauge confidence ahead of pivotal trial readouts. Stop scrolling through PDFs—start understanding Aptose Biosciences SEC documents with AI and unlock deeper Aptose Biosciences earnings report filing analysis in minutes.
Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.
Key terms:
- Facility available in up to 5 advances (≤US$2.5 m each) through 31 Dec 2025; non-revolving.
- Interest: 6% fixed; balloon repayment of all principal and accrued interest on 31 Aug 2028.
- Secured by first-ranking liens on all present and after-acquired property of Aptose and guaranteed by subsidiaries.
- Purpose limited to continued clinical development and operating costs related to Tuspetinib, an AML therapy.
- Contains customary covenants and default provisions; any re-borrowings prohibited.
The filing also triggers Item 2.03 for creation of a direct financial obligation. The debt adds leverage but supplies non-dilutive capital for ongoing trials.
Aptose Biosciences Inc. (NASDAQ: APTO) filed a Form 8-K dated June 20, 2025 to disclose an Item 7.01 Regulation FD communication. The filing states that the company issued a press release on the same date, attached as Exhibit 99.1.
The 8-K expressly notes that, under General Instruction B.2, the press release is being “furnished” rather than “filed”, meaning it is not incorporated into Exchange Act reports unless specifically referenced. No financial results, strategic transactions, or operational updates are contained in the 8-K itself, and the exhibit text is not included in the filing excerpt provided.
Aptose Biosciences Inc. (APTO) filed a Form 8-K dated June 18, 2025 to disclose the immediate resignation of director Carol Ashe, effective June 16, 2025.
The company states that Ms. Ashe’s departure was not related to any disagreement regarding operations, policies, or practices. Chairman, President & CEO William G. Rice, Ph.D. signed the filing on behalf of the board. No other management changes, financial data, or strategic transactions were reported.
FAQ
What is the current stock price of Aptose Bioscienc (APTO)?
What is the market cap of Aptose Bioscienc (APTO)?
What is the primary focus of Aptose Biosciences?
How does Aptose Biosciences approach cancer treatment?
What types of products are included in their therapeutic pipeline?
How does Aptose differentiate itself in the competitive oncology market?
What role do strategic partnerships play for Aptose Biosciences?
How is the scientific rationale behind their therapies established?
Why is precision medicine important for their treatment approach?
What are the key competitive advantages of Aptose Biosciences?
